BioPAL, Inc.: News

	PRODUCTS AND SERVICES

HOME

ABOUT US

ADVANTAGES OF BIOPAL

WHAT'S NEW

CONTACT

The Maze District of
Canyonlands National
Park in Utah >

BioPAL, Inc.: News What's New

BioPAL specializes in alternatives to radiolabeled products for applications using neutron activation (NA), magnetic resonance imaging (MRI), functional immunoassay technology (FIT), and time resolved fluorescence (TRF). BioPAL’s products are used to measure physiological processes by labeling and tracking cells, measuring kidney function, and blood flow.

What’s New is devoted to highlight current developments at BioPAL, such as the announcement of scientific research agreements, company milestones, and general news of interest to the biomedical research community.

New Product: BioPAL proudly introduces Viahance! Viahance dead-cell removal technology represents a major advance for the biomedical community. Viahance's ability to remove dead cells - as well as stripped nuclei and free oligonucleotides - from your cell culture will increase cell culture viability, improve data quality and favorably impact downstream results. Eliminating stripped nuclei and free oligonucleotides cleans up a cell preparation for future molecular biology work. As important, Viahance is provided AUTOCLAVED and does not contain foreign proteins, such as Annexin-V. To learn more, click on Viahance.

Featured Publication:
Presented at the World Conference on Regenerative Medicine.
Regenerative Medicine 2009;4:S201.

Publications:
Cell Labeling -
Feigenbaum GS, Lemberg L, Hare JM: Tracking cell fate with noninvasive imaging. J Am Coll Cardio 2009;54:1627-8.

Hale SL, Dai W, Dow JS, Kloner RA: Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment. Life Sci 2008;83:511-5.

In vivo tracking of cells using a multi-detection probe. Int Soc for Stem Cell Res, 2^nd Annual Meeting 2004, Abstract 233.

Quantitative in vivo tracking of labeled cells using a non-radioactive, non-optical technology. Stem Cells, Keystone Symposia 2004, Abstract 431.

MRI Contract Agents and Magnetic Nanopraticles Technology -
Lee J, Hirano Y, Fukunaga M, Silva AC, Duyn JH: On the contribution of deoxy-hemoglobin to MRI gray-white matter phase contrast at high field. Neuroimage;49:193-8.

Molokhia SA, Jeong EK, Higuchi WI, Li SK: Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res 2009;88:418-25.

Chen X, Astary GW, Sepulveda H, Mareci TH, Sarntinoranont M: Quantitative assessment of macromolecular concentration during direct infusion into an agarose hydrogel phantom using contrast-enhanced MRI. Magn Reson Imaging 2008;26:1433-41.

Damage to the protein synthesizing apparatus in mouse liver in vivo by magnetocytolysis in the presence of hepatospecific magnetic nanoparticles. J Magn Magn Mater 2002; 248:276-285.

Neutron Activation Technology -
Method to quantify tail vein injection technique in small animals. Contemporary Topics Lab Ani Sci 2004; 43:35-38.

Neutron-activation analysis: A novel method for the assay of iohexol. J Lab Clin Med 2003; 141:106-109.

Damage to the protein synthesizing apparatus in mouse liver in vivo by magnetocytolysis in the presence of hepatospecific magnetic nanoparticles. J Magn Magn Mater 2002; 248:276-285.

Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol 2001; 280:H108-H116.

Hepatocyte asialoglycoprotein receptor assay using stable isotopes and neutron activation analysis. Clin Chem 2000; 46:1519-1521.

New Products:
BioPAL introduces functional immunoassay technology (FIT^TM) for the measurement of kidney function.

MRI contrast agents including a unique and novel colloidal gadolinium reagent. BioPAL is the only company focused on developing new MRI contrast agents for drug discovery and research.